0000899243-22-011698.txt : 20220321
0000899243-22-011698.hdr.sgml : 20220321
20220321160511
ACCESSION NUMBER: 0000899243-22-011698
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220307
FILED AS OF DATE: 20220321
DATE AS OF CHANGE: 20220321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Werner Milton H.
CENTRAL INDEX KEY: 0001827621
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39676
FILM NUMBER: 22755759
MAIL ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc.
CENTRAL INDEX KEY: 0001750149
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
BUSINESS PHONE: 678-392-3419
MAIL ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-07
0
0001750149
Inhibikase Therapeutics, Inc.
IKT
0001827621
Werner Milton H.
3350 RIVERWOOD PARKWAY SE, SUITE 1900
ATLANTA
GA
30339
1
1
1
0
President and CEO
Common Stock
5315433
D
Stock Option (right to buy)
1.07
2022-03-07
4
A
0
125000
0.00
A
2029-03-07
Common Stock
125000
125000
D
One-third of the options will vest and become exercisable on 3/7/2023, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2023, subject to continued employment through each such vesting date.
The original Form 4, filed on March 9, 2022, is being amended by this Form 4 amendment solely to correct an error that misreported that the 24 equal monthly installments mentioned in footnote 1 would begin on the first day of April 2024, rather than the first day of April 2023 as intended.
/s/ Milton H. Werner
2022-03-21